A prior review (Price and Brust, 2019) suggested the possibility that AC7 may be “A new target for depression,” but did not propose how to “medicate this target.” An excellent review of molecules that inhibit adenylyl cyclase activity is available (Seifert et al., 2012) including many P-site inhibitors (adenosine analogues) and substituted nucleotides that act at the catalytic site of the adenylyl cyclases. The gene discussed is ADCY7; the disease is depressive disorder.